Gritstone Oncolg
Clinical‑stage biotech Gritstone bio develops innovative on‑colorectal immunotherapies GRANITE (Phase 2/3) and off‑the‑shelf SLATE (Phase 2). It also pursues a COVID‑19 vaccine (CORAL) and an HIV therapeutic, backed by bluebird bio, Gilead, and Genevant.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 231
- HQ: EmeryVille
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.